The current market price of Momelotinib and reference information from different channels

Momelotinib is a JAK1/JAK2 inhibitor mainly used to treat myelofibrosis patients with symptoms of anemia or splenomegaly. The drug reduces the release of inflammatory factors and improves bone marrow function by inhibiting the abnormally activated JAK signaling pathway, thereby relieving anemia and splenomegaly symptoms. As an innovative targeted drug, molotinib has been approved by the US FDA for the treatment of patients with moderate to severe myelofibrosis. However, it has not yet been officially launched in mainland China. If patients want to use the drug, they need to obtain it through compliant international drug channels or a prescription from an overseas hospital.

From the market price point of view, the price of the overseas US version of the original molotinib is relatively high. According to the latest data, the selling price of the original drug in the United States is about more than 200,000 yuan per course of treatment (100mg*30 tablets). The price is subject to multiple factors such as R&D costs, drug approval and import channels, which puts a heavy financial burden on ordinary patients. Some multinational pharmacies and formal overseas medical institutions provide prescription drug purchase services, but a doctor's prescription and medical certificate are required to ensure the legality and safety of the drug.

In order to meet the medication needs of more patients, some pharmaceutical companies in Laos and India have been approved to produce generic molotinib drugs in their countries. Among them, the generic version launched by Lucius Pharmaceuticals (Lucius) has been approved by the Lao Ministry of Health for marketing. The quality of the drug is basically the same as that of the original drug in terms of active ingredients and bioavailability. The market price of its 100mg*30 tablets is about 2000 yuan, which significantly reduces the cost of medication for patients. This type of generic drugs is usually provided through regular international drug agencies or medical service platforms, and requires patients to provide relevant diagnostic reports and doctor recommendation letters.

Overall, the market price gap of molotinib mainly depends on drug sources, sales channels and version differences. It is recommended that when patients consider purchasing overseas drugs, they must choose legal international drug channels and avoid purchasing through unknown channels in case the source of the drugs is unknown or there are quality risks. In the future, as the review process of molotinib advances in China, its launch is expected to bring a safer, more economical and accessible treatment option to patients with myelofibrosis.

Reference materials:https://www.drugs.com/